ArticleFrontiers in immunology2023

Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections.

Jinyoung Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.